Literature DB >> 2387661

Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson's disease.

F M Puca1, S Genco, L M Specchio, B Brancasi, R D'Ursi, A Prudenzano, A Miccoli, R Scarcia, R Martino, M Savarese.   

Abstract

Two groups of 10 patients with Parkinson's disease received doses of either 1g acetyl-L-carnitine (ALC) per day for seven days or 2g. The effects of this drug on intermittent luminous stimulation and on nocturnal sleep patterns were studied. In both cases with either dose of ALC the effect was an improvement of the H response, sleep stages and spindling activity. However a further study of the complexity of action of acetyl-L-carnitine is necessary.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2387661

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN： 0251-1649


  9 in total

1.  Acetyl-L-carnitine ameliorates mitochondrial dysfunction following contusion spinal cord injury.

Authors:  Samir P Patel; Patrick G Sullivan; Travis S Lyttle; Alexander G Rabchevsky
Journal:  J Neurochem       Date:  2010-04-23       Impact factor: 5.372

Review 2.  A review on the role of L-carnitine in the management of tamoxifen side effects in treated women with breast cancer.

Authors:  Nahla E El-Ashmawy; Rania M Khalil
Journal:  Tumour Biol       Date:  2013-12-12

3.  Effects of Mitochondrial Transplantation on Bioenergetics, Cellular Incorporation, and Functional Recovery after Spinal Cord Injury.

Authors:  Jenna L Gollihue; Samir P Patel; Khalid C Eldahan; David H Cox; Renee R Donahue; Bradley K Taylor; Patrick G Sullivan; Alexander G Rabchevsky
Journal:  J Neurotrauma       Date:  2018-04-30       Impact factor: 5.269

Review 4.  Prospects for therapeutic mitochondrial transplantation.

Authors:  Jenna L Gollihue; Alexander G Rabchevsky
Journal:  Mitochondrion       Date:  2017-05-19       Impact factor: 4.160

Review 5.  Mitochondrial-Based Therapeutics for the Treatment of Spinal Cord Injury: Mitochondrial Biogenesis as a Potential Pharmacological Target.

Authors:  Natalie E Scholpa; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2017-09-21       Impact factor: 4.030

6.  Effects of acetyl-L-carnitine on cardiac dysautonomia in Rett syndrome: prevention of sudden death?

Authors:  F Guideri; M Acampa; Y Hayek; M Zappella
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

Review 7.  Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Rick G Schnellmann
Journal:  Exp Neurol       Date:  2020-04-11       Impact factor: 5.330

8.  A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial for Efficacy of Acetyl-L-carnitine in Patients with Dementia Associated with Cerebrovascular Disease.

Authors:  YoungSoon Yang; Hojin Choi; Chan-Nyoung Lee; Yong Bum Kim; Yong Tae Kwak
Journal:  Dement Neurocogn Disord       Date:  2018-03-31

Review 9.  l-Acetylcarnitine: A Mechanistically Distinctive and Potentially Rapid-Acting Antidepressant Drug.

Authors:  Santina Chiechio; Pier Luigi Canonico; Mariagrazia Grilli
Journal:  Int J Mol Sci       Date:  2017-12-21       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.